MarketInOut Stock Screener Log In | Sign Up
 

Catalyst Pharmaceuticals Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 06/18/2026
Catalyst Pharmaceuticals Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization3,843.98 mln
Float116 mln
Earnings Date08/12/2026

EPS

1.73
Moderate

P / E

18.14
Moderately valued

Piotroski F-Score

5 / 9
Neutral

Beneish M-Score

-1.84
Caution advised

1-Year Forecast

31.67
Fairly priced

Relative Strength

61 / 100
Outperforming

Business Description

Catalyst Pharmaceuticals is a Florida-based company that develops and sells treatments for patients with rare and serious medical conditions. Its current portfolio includes three approved medicines targeting nerve and muscle disorders, including Lambert-Eaton myasthenic syndrome, certain types of epilepsy, and Duchenne muscular dystrophy. The company also works with outside partners to expand its reach through licensing and development agreements.

Key Fundamentals

EPS1.73
P/E18.14
ROE24.39
RPS4.69
ROIC81.34
ROA21.35
EBITDA, mln306
EV / EBITDA10.09
EV / EBIT11.53
Revenue, mln597
EV / Revenue5.17

Financial Strength

Altman Z-Score19.91
Piotroski F-Score 5 / 9
Beneish M-Score-1.84
Price to Intrinsic Value1.48
Price to Lynch Fair Value0.62
Price to Graham Number1.73
1-Year Target Price31.67
Shiller PE Ratio53.22
Short Ratio2.63
Short % of Float8.29

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 0.03% 42 / 100   
1 Month 0.54% 39 / 100   
2 Months 34.16% 88 / 100   
6 Months 29.72% 86 / 100   
1 Year 35.14% 76 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Contact Us